Member Search

Find a profile using the dropdown menus below.

Country
State / Region
Practice Area
Members Firms

News - 01 October 2019

Personal Genomics Taiwan, Inc. ("PGI") has filed a complaint in the U.S. District Court for the District of Delaware against Pacific Biosciences of California, Inc. ("PacBio"). The complaint asserts that PacBio's Sequel and Sequel II, as well as related commercialization activities by PacBio, infringe one or more claims of U.S. Patent No. 7,767,441 (the "'441 patent"), owned by PGI.

The '441 patent, entitled "Bioassay system including optical detection apparatuses, and method for detecting biomolecules," was issued on August 3, 2010 and covers novel apparatuses and methods for detecting biomolecules, including uses in DNA sequencing.

"PacBio has long been aware of the '441 patent and chose to make and sell products incorporating the '441 patented technology without authorization," said Dr. Johnsee Lee, CEO of PGI. "In order to protect our intellectual property from infringement, we are taking legal action against PacBio."

PGI is represented in this action by Irell & Manella LLP and Morris, Nichols, Arsht & Tunnell LLP.